Psychotropic medication use among children with autism spectrum disorders within the Simons Simplex Collection: Are core features of autism spectrum disorder related?

Autism

Volumn 18, Issue 8, 2014, Pages 933-942

  Mire, Sarah S ^a   Nowell, Kerri P ^a   Kubiszyn, Thomas ^a   Goin Kochel, Robin P ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

autism spectrum disorders; core features; psychotropic medication use; Simons Simplex Collection

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; LITHIUM; MOOD STABILIZER; PSYCHOTROPIC AGENT; SEDATIVE AGENT; TRANQUILIZER;

ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CLINICAL FEATURE; CLINICAL RESEARCH; COGNITION; COMPULSION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PREVALENCE; SIMONS SIMPLEX COLLECTION; ADOLESCENT; AGE DISTRIBUTION; CHILD DEVELOPMENT DISORDERS, PERVASIVE; PRESCHOOL CHILD; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; AGE DISTRIBUTION; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; SEVERITY OF ILLNESS INDEX;

EID: 84908622091     PISSN: 13623613     EISSN: 14617005     Source Type: Journal    
DOI: 10.1177/1362361313498518     Document Type: Article

References (34)

1. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders. 2003 ; 33: 527-534
2. Aman MG, Lam KSL, Van Bourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology. 2005 ; 15: 116-126
3. Brown RT, Antonuccio DO, DuPaul GJ, et al Childhood Mental Health Disorders: Evidence Base and Contextual Factors for Psychosocial, Psychopharmacological, and Combined Interventions. Washington, DC: APA ; 2008 :
4. Correll CV, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association. 2009 ; 302: 1765-1773
5. Elliott CD Differential Ability Scales - Second Edition. San Antonio, TX: Harcourt Assessment ; 2007 :
6. Filipek P, Steinberg-Epstein R, Book T. Intervention for autistic spectrum disorders. Neurorx: The Journal of the American Society for Experimental Neurotherapeutics. 2006 ; 3 (2). 207-216
7. Fischbach GD, Lord C. The Simons Simplex Collection: a resource for identification of autism genetic risk factors. Neuron. 2010 ; 68: 192-195
8. Frazier TW, Shattuck PT, Narendorf SC, et al. Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported ADHD. Journal of Child and Adolescent Psychopharmacology. 2011 ; 21 (6). 571-579
9. Frazier TW, Youngstrom EA, Haycock T, et al. Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology. 2010 ; 20 (3). 167-177
10. Gerhard T, Chavez B, Olfson M, et al. National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder. Journal of Clinical Psychopharmacology. 2009 ; 29: 307-310
11. Goin-Kochel RP, Myers BJ, Mackintosh VH. Parental reports on the use of treatments and therapies for children with autism spectrum disorders. Research in Autism Spectrum Disorders. 2007 ; 1: 1195-1209
12. Green VA, Pituch KA, Itchon J, et al. Internet survey of treatments used by parents of children with autism. Research in Developmental Disabilities. 2006 ; 27: 70-84
13. Huffman LC, Sutcliffe TL, Tanner ISD, et al. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments. Journal of Developmental and Behavioral Pediatrics. 2011 ; 32 (1). 56-68
14. Kelly AB, Garnett MS, Attwood T, et al. Autism spectrum symptomatology in children: the impact of family and peer relationships. Journal of Abnormal Child Psychology. 2008 ; 36: 1069-1081
15. Kubiszyn T, Mire S, Dutt S, et al. Significant differences in pediatric psychotropic side effects: implications for school performance. School Psychology Quarterly. 2012 ; 27 (1). 4-28
16. Leyfer O, Folstein S, Bacalman S, et al. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. Journal of Autism and Developmental Disorders. 2006 ; 36 (7). 849-861
17. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule - generic: a standard measure of communication deficits associated with the spectrum of autism. Journal of Autism and Developmental Disorders. 2000 ; 30: 205-223
18. Lubetsky MJ, Handen BL. Medication treatment in autism spectrum disorder. Speaker's Journal. 2008 ; 8: 97-107
19. Mandell DS, Morales KH, Marcus SC, et al. Psychotropic medication use among medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008 ; 121: 441-448
20. Mullen EM Mullen Scales of Early Learning. Circle Pines, MN: American Guidance Service Inc ; 1995 :
21. Myers SM, Johnson CP. Management of children with autism spectrum disorders. Pediatrics. 2007 ; 120 (5). 1162-1182
22. Olfson M, Crystal S, Huang C, et al. Trends in antipsychotic drug use by very young, privately insured children. Journal of the American Academy of Child and Adolescent Psychiatry. 2010 ; 49 (1). 13-23
23. Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology. 2007 ; 17: 348-355
24. Panagiotopoulos C, Ronsley R, Elbe D, et al. First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2010 ; 90: 124-137
25. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine. 2009 ; 360: 225-235
26. Rosenberg RE, Mandell DS, Farmer JE, et al. Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry. Journal of Autism and Developmental Disorders. 2010 ; 40: 342-351
27. Rutgers AH, Bakermans-Kranenburg MJ, Van Ijzendoorn MH, et al. Autism and attachment: a meta-analytic review. Journal of Child Psychology and Psychiatry. 2004 ; 45: 1123-1134
28. Rutter M, Le Couter A, Lord C Autism Diagnostic Interview-Revised. Los Angeles, CA: WPS ; 2003 :
29. Semrud-Clikeman M, Walkowiak J, Wilkinson A, et al. Executive functioning in children with Asperger syndrome, ADHD-predominately inattentive type, and controls. Journal of Autism and Developmental Disorders. 2010 ; 40 (8). 1017-1027
30. Simonoff E, Pickles A, Charman T, et al. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry. 2008 ; 47 (8). 921-929
31. Wechsler D Wechsler Intelligence Scale for Children - Fourth Edition. San Antonio, TX: Psychological Corporation ; 2003 :
32. Williamson ED, Martin A. Psychotropic medications in autism: practical considerations for parents. Journal of Autism and Developmental Disorders. 2012 ; 42: 1249-1255
33. Witwer A, Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology. 2005 ; 15 (4). 671-681
34. Zito J, Safer D, dosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Archives of Pediatrics and Adolescent Medicine. 2003 ; 157 (1). 17-25